Literature DB >> 3013106

Primary chest wall tumors: factors affecting survival.

R M King, P C Pairolero, V F Trastek, J M Piehler, W S Payne, P E Bernatz.   

Abstract

Between 1955 and 1975, chest wall resection was done in 90 patients for primary chest wall tumors. Ages ranged from 8 to 96 years (mean, 44.3 years). A painful mass was the most common sign and symptom. Eighty-two tumors (91.1%) were located in the lateral chest wall and eight, in the anterior thorax. The tumor was malignant in 71 patients (78.9%) and benign in 19. All patients with benign tumors had complete excision and are currently free from disease. Malignant fibrous histiocytoma, chondrosarcoma, and rhabdomyosarcoma constituted 62% of the malignant neoplasms. Most malignancies were treated by wide resection. There were no thirty-day operative deaths. Overall 1-, 5-, and 10-year survival was 89%, 57%, and 49%, respectively. Recurrent tumor developed in 37 patients (52%); 5-year survival, however, was only 17% after recurrence. Cell type and extent of invasion significantly influenced survival. Both chondrosarcoma and rhabdomyosarcoma had a better prognosis than malignant fibrous histiocytoma (p less than 0.05). We conclude that early resection is the treatment of choice for primary malignant chest wall tumors and that development of recurrent disease is an ominous event.

Entities:  

Mesh:

Year:  1986        PMID: 3013106     DOI: 10.1016/s0003-4975(10)63067-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  43 in total

Review 1.  Chondrosarcoma of the rib.

Authors:  Takehiko Shimoyama; Ryuta Suzuki; Katsuo Yoshiya; Yasushi Yamato; Teruaki Koike
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-04

2.  Primary pleural lymphoma: a rare case and a synopsis of the literature.

Authors:  Xiaohu Ru; Mingjian Ge; Li Li; Yidan Lin; Lunxu Liu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

3.  Radical resection of a giant recurrent chondrosarcoma of the anterior chest wall.

Authors:  Necati Çitak; Alper Çelikten; Muzaffer Metin; Atilla Pekçolaklar; Atilla Gürses
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-07-14

4.  Surgical therapy of primary malignant bone tumours and soft tissue sarcomas of the chest wall: a two-institutional experience.

Authors:  Joerg Friesenbichler; Andreas Leithner; Werner Maurer-Ertl; Joanna Szkandera; Patrick Sadoghi; Andreas Frings; Alfred Maier; Dimosthenis Andreou; Reinhard Windhager; Per-Ulf Tunn
Journal:  Int Orthop       Date:  2014-03-15       Impact factor: 3.075

5.  Epithelioid hemangioendothelioma originating from the chest wall with rib metastases.

Authors:  Junichi Shimamura; Moriyuki Kiyoshima; Hisashi Suzuki; Miyuki Kitahara; Yuji Asato; Tatsuo Iijima; Ryuta Amemiya
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-01-08

6.  Review of chest wall tumors: a diagnostic, therapeutic, and reconstructive challenge.

Authors:  Elizabeth A David; M Blair Marshall
Journal:  Semin Plast Surg       Date:  2011-02       Impact factor: 2.314

Review 7.  Mini review: surgical management of primary chest wall tumors.

Authors:  Takamasa Ito; Hidemi Suzuki; Ichiro Yoshino
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-10-24

8.  Clinical experience with titanium mesh in reconstruction of massive chest wall defects following oncological resection.

Authors:  Haitang Yang; Jicheng Tantai; Heng Zhao
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

9.  The novel use of small intestinal submucosal matrix for chest wall reconstruction following Ewing's tumour resection.

Authors:  Feilim Murphy; Martin T Corbally
Journal:  Pediatr Surg Int       Date:  2007-02-08       Impact factor: 1.827

10.  A case of radiation-induced sternal malignant fibrous histiocytoma treated with neoadjuvant chemotherapy and surgical resection.

Authors:  Bulent Kocer; Gultekin Gulbahar; Bulent Erdogan; Burcin Budakoglu; Selim Erekul; Koray Dural; Unal Sakinci
Journal:  World J Surg Oncol       Date:  2008-12-30       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.